Disease · MONDO_0000430
Comparisons in its trials32
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 32
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A+CHP vs CHOP: Objective Response Rate (ORR) Per IRF at End of Treatment | 188 of 226 | 163 of 226 | 452 | NCT01777152 | Trial comparisons |
| A+CHP vs CHOP: Complete Remission (CR) Rate Per IRF at End of Treatment (EOT) | 153 of 226 | 126 of 226 | 452 | NCT01777152 | Trial comparisons |
| Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: deaths from any cause | 52 of 133 | 16 of 22 | 155 | NCT04703192 | Trial comparisons |
| Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: serious adverse events | 53 of 133 | 15 of 22 | 155 | NCT04703192 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): deaths from any cause | 6 of 47 | 5 of 84 | 131 | NCT00007345 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): Number of Participants With Adverse Events | 47 of 47 | 84 of 84 | 131 | NCT00007345 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): serious adverse events | 20 of 47 | 38 of 84 | 131 | NCT00007345 | Trial comparisons |
| CD30 <1% [Local Laboratory Assessment] vs CD30 1% to <10% [Local Laboratory Assessment]: deaths from any cause | 11 of 34 | 13 of 48 | 82 | NCT04569032 | Trial comparisons |
| CD30 <1% [Local Laboratory Assessment] vs CD30 1% to <10% [Local Laboratory Assessment]: serious adverse events | 15 of 34 | 16 of 48 | 82 | NCT04569032 | Trial comparisons |
| Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): deaths from any cause | 31 of 47 | 11 of 13 | 60 | NCT01431209 | Trial comparisons |
| Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): serious adverse events | 22 of 47 | 7 of 13 | 60 | NCT01431209 | Trial comparisons |
| Phase 1 vs Phase 2: deaths from any cause | 11 of 26 | 0 of 25 | 51 | NCT01998035 | Trial comparisons |
| Phase 1 vs Phase 2: serious adverse events | 11 of 26 | 12 of 25 | 51 | NCT01998035 | Trial comparisons |
| Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): deaths from any cause | 9 of 39 | 1 of 4 | 43 | NCT02561273 | Trial comparisons |
| Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): serious adverse events | 14 of 39 | 2 of 4 | 43 | NCT02561273 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Not Evaluable (NE) | 4 of 9 | 2 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Progressive Disease (PD) | 2 of 9 | 0 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Partial Response (PR) | 1 of 9 | 1 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Stable Disease (SD) | 2 of 9 | 4 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): deaths from any cause | 3 of 9 | 1 of 7 | 16 | NCT02314247 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000430/comparisons